Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease

Table 2 Association of baseline characteristics with SGLT2 inhibitor use

	Adjusted odds ratio
Age (per 10-year increase)	0.80 [0.65 to 0.99] (P = 0.042)
Body mass index (per 5 kg/m² increase)	1.40 [1.09 to 1.79] (P = 0.008)
Dyslipidemia	1.76 [0.63 to 4.95] (P = 0.28)
Coronary artery disease	1.39 [0.94 to 2.04] (P = 0.097)
HbA1c (per 1% [10.93-mmol/mol] increase)	1.31 [1.14 to 1.49] (P < 0.001)
Statin use	1.55 [0.91 to 2.65] (P = 0.11)

Data are adjusted odds ratios [95% confidence intervals] (P values), derived from the multivariable logistic regression model including all the variables in the table, which were significantly different between patients treated with and without a SGLT2 inhibitor (see Table 1). HbA1c, hemoglobin A1c; SGLT2, sodium-glucose co-transporter 2

ISSN: 1475-2840